[CAS NO. 1469924-27-3] Atglistatin
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1469924-27-3]
Store
Catalog
SLK-S7364
Brand
Selleck
CAS
1469924-27-3
DESCRIPTION [1469924-27-3]
Overview
| MDL | MFCD28009494 |
|---|---|
| Molecular Weight | 283.37 |
| Molecular Formula | C17H21N3O |
| SMILES | O=C(NC1=CC(C2=CC=C(N(C)C)C=C2)=CC=C1)N(C)C |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5290 mL | 17.6448 mL | 35.2896 mL |
| 5 mM | 0.7058 mL | 3.5290 mL | 7.0579 mL |
| 10 mM | 0.3529 mL | 1.7645 mL | 3.5290 mL |
| 50 mM | 0.0706 mL | 0.3529 mL | 0.7058 mL |
Description
Atglistatin is a highly potent, and selective inhibitor of with of 0.7 μM, high selectivity over other key metabolic lipases.
Targets
| ATGL [1] (Cell-free assay) |
| 0.7 μM |
In vitro
Atglistatin inhibits lipolysis in cell and organ cultures by targeting ATGL with no cytotoxicity up to a concentration of 50 μM.
In vivo
In vivo, Atglistatin (i.p.) results in Dose and time-dependent inhibition of lipolysis. Oral treatment of Atglistatin causes a dose-dependent decrease in FA and glycerol of up to 50% and 62%, respectively, and also causes a strong reduction in plasma TG levels (43%). In addition, Atglistatin shows a distinct tissue distribution and primarily accumulates in liver and adipose tissue.
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.